Fig. 1: Median exposure per group (Cmin). | British Journal of Cancer

Fig. 1: Median exposure per group (Cmin).

From: Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients

Fig. 1

Boxplots of median Cmin per patient in all patients, the Adequate- and the Low-group, also shown divided in a before and after intervention subgroup. Adequate exposure group: patients with all pharmacokinetic levels 8.4 ng/mL. Low exposure group: patients with ≥1 pharmacokinetic level <8.4 ng/mL. Before intervention: patients in the Low-group before intervention. After intervention: patients in the Low-group after intervention. *: significant (p-value < 0.05). **: only including patients who had an evaluable intervention. Cmin minimal plasma concentrations at steady-state.

Back to article page